In response, much of the current research has been focused on a functional cure for HIV. Instead of eradicating the virus, a functional cure would aim to suppress viral activity to levels where it cannot cause the body any harm and do so without the ongoing use of drugs.
At its heart, a functional cure aims to replicate the mechanisms that protect elite controllers—people with HIV who experience no disease progression—from developing symptomatic disease.
Most scientists believe that a functional cure will require a multi-pronged approach to not only extract the virus from tissues and cells where it is embedded but also to spur the immune system to better fight and control the infection.
Goals and Challenges
There is no consensus on how a functional cure might work, and there are enormous gaps in science to be filled before one can be fully realized. With that said, there are several approaches that scientists are actively pursuing as well as key challenges they have yet to overcome.
Immunologic Control
Elite controllers, also known as long-term non-progressors, account for less than 1% of people living with HIV. They have built-in immune mechanisms that manage to keep the virus under control without antiretroviral drugs. Some, in fact, have lived with the virus for more than 30 years with no signs of disease progression.
There are many mechanisms that contribute to this effect, but one that is of special interest involves a unique body of proteins called broadly neutralizing antibodies (bNaBs). This is a rare type of antibody that can neutralize the multitude of HIV variants that exist within a single viral population.
While scientists are exploring ways to stimulate the immune system to produce these and other bNaBs, results thus far have fallen short. In non-elite progressors, any attempt to stimulate an individual bNaB is typically met with a contradictory response in which the immune system will “reboot” the antibody production to restore homeostasis (an established state of equilibrium).
Until this barrier is overcome, scientists will be hard-pressed to mimic the natural defenses afforded to elite controllers.
Viral Reservoirs
While some scientists believe that a functional cure can be achieved solely by suppressing circulating viruses, others remain doubtful. This is because HIV quickly embeds itself into cells and tissues throughout the body, creating viral reservoirs soon after infection. There, it remains in a latent state, hidden from immune detection.
If a person on antiretroviral therapy suddenly stops treatment, these reservoirs can suddenly activate and release new viruses into circulation, causing a viral rebound.
Because the virus is hidden within cells and tissues as a provirus, replicating silently in tandem with the host, bNaBs cannot actively target them for neutralization. It is only when they are released from these reservoirs that bNaBs (or some other agent) can act.
Many scientists contend that some form of “kick-kill” (a.k.a. “shock-kill”) strategy is needed to render a functional cure. This is a strategy in which latency-reversing drugs are used to purge the reservoirs, after which another agent (or agents) provides viral control and prevents the establishment of new reservoirs.
Scientists know that the reservoirs can be cleared based on the Berlin Patient case, in which an American living in Germany experienced complete viral clearance after undergoing an experimental stem cell transplant. Even so, that procedure is considered too risky to be a viable option.
Immune Exhaustion
Another mechanism that scientists need to overcome is immune exhaustion. This is a phenomenon that contributes to HIV progression, wherein the immune system increasingly becomes “blind” to the virus.
Chronic immune activation, in which the immune system is left in a constant state of alert, is believed to be the cause of this problem. When it occurs, the immune system—recognizing that chronic activation is abnormal—will respond by producing a protein called programmed death-1 (PD-1). This is the protein that the body uses to down-regulate the immune response and prevent overactivation.
Even if bNaBs or other agents have the potential to neutralize circulating HIV, they may be less able to do so unless immune exhaustion is reversed.
Is a Functional Cure the Answer?
As ideal as it may seem to have a natural defense to HIV, there are challenges that even elite controllers face. Even if the virus is naturally suppressed by the immune system, it is still there, actively generating low-level inflammation.
Studies have shown that, over time, this can trigger the early onset of heart diseases, including atherosclerosis and hypertrophic cardiomyopathy (thickening of the heart muscle).
Other studies have shown that elite controllers have just as many hospitalizations as their non-elite controller counterparts and are more likely to experience heart diseases than people on fully suppressive antiretroviral therapy.
As a result, many researchers endorse the use of antiretroviral therapy in elite controllers—not to prevent HIV-related diseases but rather non-HIV-related ones.
Until scientists are better able to answer these and other questions, the best thing to do is stay the course and adhere to antiretroviral drugs that have not only increased life expectancy to near-normal levels but have reduced the incidence of severe, HIV-related and non-HIV-related illnesses by 61%.
.
